Guidance to support primary care prescribers and pharmacists is available from the MLCSU Coronavirus guidance resource page. Links are provided to national resources and regional documents produced by MLCSU, RDTC, and SPS for use by Pan Mersey APC, LSCMMG, and GMMMG.
The list of resources will be updated as new material becomes available so please check back regularly for updates.
The Pan Mersey APC supports the use of COVID-specific guidance issued by NICE, and NHS England and NHS Improvement. During the COVID pandemic this will supersede any APC advice. In the absence of any COVID-specific advice then the usual Pan Mersey guidance and RAG rating will still apply unless otherwise indicated.
This section contains a list of the policy recommendations of the Pan Mersey Area Prescribing Committee.
Reviews of the new medicines have been conducted by our pharmacists using a number of resources including National Institute for Health and Clinical Excellence (NICE) which is a Special health Authority (SHA) set up in 1999. It is used to give advice to the NHS on best clinical practice including the clinical and cost effectiveness of drugs and other treatments.
The Pan Mersey Area Prescribing Committee recommends the prescribing of ELUXADOLINE Tablets (Truberzi®▼) following specialist initiation for irritable bowel syndrome with diarrhoea in adults in accordance with NICE TA471.
Red NHS West Lancashire CCG
The Pan Mersey Area Prescribing Committee recommends the prescribing of etanercept injection for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis and adult-onset Still’s disease, as well as in patients fitting other criteria commissioned by Pan Mersey CCGs, as listed.
The Pan Mersey Area Prescribing Committee does not recommend the prescribing of EVOLOCUMAB injection (Repatha SureClick®▼) for reduction of cardiovascular risk in adults with established atherosclerotic cardiovascular disease.
The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of EZETIMIBE (Ezetrol®) for the prevention of cardiovascular events in patients with cholesterol levels within target range.